Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STERLING-PMR
ISRCTN17828080Phase 3Active, not recruiting
- Sponsor
- University of Leeds
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of methotrexate, leflunomide and prednisolone in polymyalgia rheumatica (PMR) (2 arms), sponsored by University of Leeds. Primary endpoint: Mean participant-reported cumulative prednisolone dose. Started Jan 2024; status: active, not recruiting.
02
Drugs
methotrexateleflunomideprednisolone
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on ISRCTN17828080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN17828080.